Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.

International Clinical Psychopharmacology
Ayman Antoun ReyadRaafat Mishriky

Abstract

Brexpiprazole is a new atypical antipsychotic for schizophrenia management and as adjunct in major depressive disorder (MDD). We searched randomized controlled trials (RCT) to review brexpiprazole efficacy and tolerability in acute management of schizophrenia and MDD using PubMed, EUDRACT, ClinicalTrials.gov and Cochrane Central Register of Controlled Trials. A meta-analysis was conducted using the identified 14 RCT to assess its efficacy using positive and negative syndrome scale (PANSS), clinical global impressions - severity of illness (CGI-S), personal and social performance scale (PSP), Montgomery-Åsberg depression rating scale (MADRS), Sheehan disability scale (SDS) and Hamilton depression rating scale (HDRS17). The mean difference comparing brexpiprazole and placebo were PANSS -4.48, CGI-S -0.23 and PSP 3.24 favoring brexpiprazole. Compared to aripiprazole and quetiapine, brexpiprazole showed similar efficacy. In MDD, brexpiprazole showed efficacy compared to placebo demonstrated by MADRS -1.25, SDS -0.37 and HDRS17 -1.28. Brexpiprazole was associated with side effects including akathisia risk ratio (RR) = 1.72; weight increase RR = 2.74 and somnolence RR = 1.87. Compared to 4 mg, brexpiprazole 2 mg was associated with l...Continue Reading

References

Feb 25, 1999·The New England Journal of Medicine·N C Andreasen
Jan 12, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Anissa Abi-Dargham, Marc Laruelle
Jan 5, 2011·Journal of Clinical Epidemiology·Gordon GuyattHolger J Schünemann
Jul 26, 2011·BMJ : British Medical Journal·Jonathan A C SterneJulian P T Higgins
Aug 2, 2011·Journal of Clinical Epidemiology·Gordon H GuyattHolger J Schünemann
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Mar 22, 2014·International Journal of Epidemiology·Zachary SteelDerrick Silove
Jun 21, 2014·The Journal of Pharmacology and Experimental Therapeutics·Kenji MaedaTetsuro Kikuchi
Sep 17, 2014·The Journal of Pharmacology and Experimental Therapeutics·Chris A OosterhofPierre Blier
Feb 18, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Tamaki IshimaKenji Hashimoto
May 28, 2016·Expert Opinion on Investigational Drugs·Ricardo P GarayPierre-Michel Llorca
Jul 6, 2016·The Journal of Clinical Psychiatry·Maurizio FavaRoss A Baker
Jan 31, 2017·Archives of Gerontology and Geriatrics·Henry C Ndukwe, Prasad S Nishtala
Mar 24, 2017·Therapeutics and Clinical Risk Management·Nishant B ParikhAnita H Clayton
Nov 13, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Hanna E van den MunkhofFrancesc Artigas
Dec 12, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Hagit CohenJørn Arnt
Jun 5, 2018·Annals of Translational Medicine·Wilbert S Aronow, Tatyana A Shamliyan
Jan 24, 2019·Drugs·James E Frampton
Jan 31, 2019·Neuropsychiatric Disease and Treatment·Kristen Ward, Leslie Citrome
Feb 26, 2019·Journal of Affective Disorders·E Sherwood BrownChastity Escalante
May 9, 2019·Pharmacology·Keisuke ObaraYoshio Tanaka
Jul 1, 2019·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Filippo CorponiAlessandro Serretti
Jul 11, 2019·Psychiatria Danubina·Ayman Antoun Reyad, Raafat Mishriky
Aug 23, 2019·Expert Opinion on Pharmacotherapy·Michele FornaroDomenico De Berardis
Sep 29, 2019·Chemical Research in Toxicology·Bingbing ChenGuo-Xin Hu

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA

Clinical Trials Mentioned

NCT00905307
NCT01052077
NCT00797966
NCT01810380
NCT01838681
NCT02194933
NCT01942785
NCT03257865
NCT03287869
NCT03259555

Software Mentioned

RevMan
Review Manager

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Annals of Pharmacotherapy
Marija MarkovicMegan Maroney
Expert Opinion on Pharmacotherapy
Wen-Yu HsuChieh-Hsin Lin
© 2021 Meta ULC. All rights reserved